Paris: The World Health Organization approved two new Covid-19 treatments on Friday, fostering a warehouse tool along with vaccines to prevent severe diseases and deaths from viruses.
The news came as an omicron case filling a hospital throughout the world with those who predict half of Europe to be infected in March.
In their recommendations in the British Medical Journal BMJ, the expert said the Beritinib drug arthritis used with corticosteroids to treat severe or critical covid patients caused a better survival rate and reduced ventilator needs.
Experts also recommend synthetic antibodies for people with non-serious Covid at the highest risk of hospitalization, such as elderly, people with immunodeficiency or chronic diseases such as diabetes.
The benefits of Sotrovimab for people who are not at risk of being hospitalized are considered insignificant and WHO says its effectiveness of a new variant like Omicron is “still uncertain”.
Only three other treatments for Covid-19 who have received who agreed, began with corticosteroids for severe pain in September 2020.
Corticosteroids are not expensive and many available and fight inflammation that usually accompanies heavy cases.
The tililizumab and sarilumab arthritis drug, which is supported in July, is an IL-6 inhibitor that suppresses a dangerous reaction from the immune system with the SARS-COV-2 virus.
Larisitinib is in a different drug class known as Janus Kinase inhibitors, but falls under the same guidelines as IL-6 inhibitors.
“When both are available, select one based on problems including cost and doctor experience,” said the guidelines.
The treatment of synthetic regeneron antibodies was approved by WHO in September and the guidelines that Sotrovimab said can be used for the same type of patient.
WHO’s Covid treatment recommendations are updated regularly based on new data from clinical trials.